Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07730892
Active, not recruiting Not applicable

PCNL Versus RIRS for Management of Stones in Solitary Kidney

NCT07730892 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mansoura University
Phase
Not applicable
Started
2024-11-23
Last updated
2026-07-28

Condition(s) studied

Renal Stones

Investigational drug(s) / intervention(s)

retrograde intra renal surgery (RIRS)percutaneous nephrolithotomy (PCNL)

retrograde intra renal surgery (RIRS): standard retrograde intrarenal surgery (RIRS) for management of stones in solitary kidney

percutaneous nephrolithotomy (PCNL): standard percutaneous nephrolithotomy (PCNL) for management of stones in solitary kidney

Study summary

Few studies compared PCNL and RIRS for stones in solitary kidney. Current guidelines do not provide clear recommendations concerning the management of renal stones in patients with solitary kidney. The study aims to compare the safety and efficacy of the use of percutaneous nephrolithotomy (PCNL) and flexible ureteroscopy in the treatment of renal stones \_ ≤ 3 cm in largest diameter through a prospective non randomized study in the period between August 2024 and August 2026. Stone-free rate will be assessed by NCCT done at 1st day postoperative and after 3 months. For Evaluation of kidney function postoperatively, creatinine clearance will be done after 1month and renal isotope scan will be done after 3 months. In addition, the results will be compared to the data of the patients with solitary kidney and renal stones who were retrospectively treated by PCNL or RIRS in the period between 2002 and 2024. The cases should fulfil the same inclusion criteria of the prospective study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with anatomical or functional solitary kidney. * Renal stones ≤ 3 cm in largest diameter- as measured by non-contrast spiral CT * Age ≥ 18 years. Exclusion Criteria: * Patients who did not meet the above criteria. * bleeding diathesis or those on anticoagulant therapy. * concomitant pathology as ureteric stricture or renal congenital anomalies .

Primary outcome measure(s)

  • stone free rate — within 3 months after surgery
    Stone-free status: it will be assessed by NCCT (defined as the absence of any stones or presence of only clinically insignificant residual stones \< 4 mm as measured by NCCT). Sub classified to * Initial stone free rate (1st day postoperative) * Final stone free rate (after 3 months)

Trial sites (1)

FacilityCityRegionStatus
Urology and Nephrology center , Mansoura University Al Mansurah Dakahlia Governorate

More Mansoura University trials in Egypt

Role of HFNC During FOB in Patients With Respiratory Failure Recruiting
FANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial Starting soon
Fully Versus Partially Guided Implants Placement: Measurement of Accuracy of Implant Position and Passivity of Superstructures. Active, not recruiting
Maxillary and Mandibular Nerve Block Recruiting
New Vital Pulpotomy Medications in Primary Molars Active, not recruiting

Other trials for the same condition

Efficacy and Safety of Flexible Ureteroscopy Versus Percutaneous Nephrolithotomy in Management of Staghorn Stones Starting soon
Tamsulosin and Intraureteral Aminophylline for Ureteral Access During RIRS Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07730892 on ClinicalTrials.gov ↗ ← All trials in Egypt